pf 06751979 (Pfizer Inc)
86
Structured Review
Pfizer Inc
pf 06751979
Pf 06751979, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-06751979/06751979+pf/pm41906332-113-0-3
Average 86 stars, based on 1 article reviews
Pf 06751979, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pf-06751979/06751979+pf/pm41906332-113-0-3
Average 86 stars, based on 1 article reviews
pf 06751979 - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
other:Article Title: Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases Article Snippet: Article Title: New evolutions in the BACE1 inhibitor field from 2014 to 2018. Article Snippet: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the potential of disease-modifying treatment for Alzheimer’s disease (AD).. Since 2014, major breakthroughs have appeared in the field of BACE1 inhibitors.. This review provides an overview of amidinebased BACE1 inhibitors between 2014 and 2018. Article Title: BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future? Article Snippet: PF-06751979 is a small-molecule BACE1 inhibitor, with high BACE1 selectivity compared to Article Title: Selective Secretase Targeting for Alzheimer’s Disease Therapy Article Snippet: Alzheimer’s disease (AD) is associated with marked atrophy of the cerebral cortex and accumulation of amyloid plaques and neurofibrillary tangles.. Amyloid plaques are formed by oligomers of amyloid(A ) in the brain, with a length of 42 and 40 amino acids.. -secretase cleaves amyloidprotein precursor (A PP) producing the membrane-bound fragment CTF and the soluble fragment sA PP with neuroprotective activity; -secretase produces membrane-bound fragment CTF and a soluble fragment sA PP . Article Title: Is It the Twilight of BACE1 Inhibitors? Article Snippet: Article Title: BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future? Article Snippet: Nevertheless, in Article Title: JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. Article Snippet: The discovery of a novel 2-aminotetrahydropyridine class of BACE1 inhibitors is described.. Their pKa and lipophilicity were modulated by a pending sulfonyl group, while good permeability and brain penetration were achieved via intramolecular hydrogen bonding.. BACE1 selectivity over BACE2 was achieved in the S3 pocket by a novel bicyclic ring system. Article Title: Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). Article Snippet: Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020) Frederik Rombouts , Ken-ichi Kusakabe , Chien-Chi Hsiao & Harrie J. M. Gijsen To cite this article: Frederik Rombouts , Ken-ichi Kusakabe , Chien-Chi Hsiao & Harrie J. M. Gijsen (2020): Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020), Expert Opinion on Therapeutic Patents, DOI: 10.1080/13543776.2021.1832463 To link to this article: https://doi.org/10.1080/13543776.2021.1832463 |